SNK 863
Alternative Names: Recel; SK 863Latest Information Update: 10 Sep 1997
At a glance
- Originator Sanwa Kagaku Kenkyusho
- Developer NK Curex; Sanwa Kagaku Kenkyusho
- Class
- Mechanism of Action Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Skin ulcer